Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Medical Case Reports
Published in: Journal of Medical Case Reports 1/2022

Open Access 01-12-2022 | Ultrasound | Case report

Patients with Peyronie’s disease achieve complete plaque regression after multimodal treatment with antioxidants: a case series

Authors: Gianni Paulis, Giovanni De Giorgio

Published in: Journal of Medical Case Reports | Issue 1/2022

Login to get access

Abstract

Background

Peyronie’s disease is a chronic inflammatory condition of the corpora cavernosa characterized by the formation of plaque in the tunica albuginea, which results in penile deformity. Conservative medical approaches encompass oral, topical, and physical treatment. Only two cases of patients with Peyronie’s disease with complete plaque regression after treatment have been described in literature.

Case presentation

Case 1: A 50-year-old Caucasian man with penile pain and double penile curvature of 5° (left ventrolateral), palpable nodule, and normal penile rigidity. The patient underwent multimodal therapy (oral antioxidants + topical diclofenac gel). At follow-up after over 4 years of treatment, the patient no longer complained of any penile deformity or pain. Ultrasound examination did not show any plaque. Case 2: A 26-year-old Caucasian man with lateral-right penile curvature of 30° (previous congenital curvature of 15°), palpable nodule, and normal penile rigidity. The patient underwent multimodal therapy (oral antioxidants + topical diclofenac gel + penile injections/pentoxifylline). After 28 months of treatment, the patient presented a lateral right curve of 15° at follow-up, similar to the original congenital penile curvature. Ultrasound examination no longer showed any plaque. Case 3: A 36-year-old Caucasian man with penile pain and a complex penile curvature of 15° and 20° (left dorsolateral), palpable nodule, and normal penile rigidity. The patient underwent multimodal therapy (oral antioxidants + topical diclofenac gel + penile injections/pentoxifylline). At follow-up after 28 months of treatment, the patient presented a dorsal curve (10°) similar to the original congenital curvature. Penile palpation did not detect any nodules, and ultrasound no longer showed any plaque.

Conclusions

This study demonstrates that our multimodal therapy is able to completely regress plaque, as demonstrated in our previously published article. Peyronie’s disease has the potential to be treated conservatively with good results. However, this method of treatment needs to be combined with accurate ultrasound assessment, performed using a sufficiently advanced machine by an experienced operator.
Literature
1.
Weidner W, Schroeder-Printzen I, Weiske WH, et al. Sexual dysfunction in Peyronie’s disease: an analysis of 222 patients without previous local plaque therapy. J Urol. 1997;157(1):325–8.PubMedCrossRef
2.
Pryor JP, Ralph DJ. Clinical presentations of Peyronie’s disease. Int J Impot Res. 2002;14(5):414–7.PubMedCrossRef
3.
Nelson CJ, Diblasio C, Kendirci M, et al. The chronology of depression and distress in men with Peyronie’s disease. J Sex Med. 2008;5(8):1985–90.PubMedCrossRef
4.
Devine CJJ, Somers KD, Jordan GH. Proposal: trauma as a cause of Peyronie’s lesion. J Urol. 1997;157:285–90.PubMedCrossRef
5.
Somers KD, Dawson DM. Fibrin deposition in Peyronie’s disease plaque. J Urol. 1997;157(1):311–5.PubMedCrossRef
6.
7.
Sikka SC, Hellstrom WJG. Role of oxidative stress and antioxidants in Peyronie’s disease. Int J Impot Res. 2002;14(5):353–60.PubMedCrossRef
8.
Paulis G, Romano G, Paulis L, et al. Recent pathophysiological aspects of Peyronie’s disease: role of free radicals, rationale, and therapeutic implications for antioxidant treatment—literature review. Adv Urol. 2017;2017:4653512.PubMedPubMedCentralCrossRef
9.
Yousif A, Natale C, Hellstrom WJG. Conservative therapy for Peyronie’s disease: a contemporary review of the literature. Curr Urol Rep. 2021;22(2):6.PubMedCrossRef
10.
Natale C, McLellan DM, Yousif A, et al. Review of intralesional collagenase clostridium histolyticum injection therapy and related combination therapies in the treatment of Peyronie’s disease (an update). Sex Med Rev. 2021;9(2):340–9.PubMedCrossRef
11.
Paulis G. Combination therapy (in the treatment of Peyronie’s disease). In: Cavallini G, Paulis G, editors. Peyronie’s disease. A comprehensive guide. Switzerland: Springer International Publishing; 2015. p. 97–105.
12.
Eri LM, Thomassen H, Brennhovd B, et al. Accuracy and repeatability of prostate volume measurements by transrectal ultrasound. Prostate Cancer Prostatic Dis. 2002;5(4):273–8.PubMedCrossRef
13.
Lee JS, Chung BH. Transrectal ultrasound versus magnetic resonance imaging in the estimation of prostate volume as compared with radical prostatectomy specimens. Urol Int. 2007;78(4):323–7.PubMedCrossRef
14.
Gallo L, Sarnacchiaro P. Ten-year experience with multimodal treatment for acute phase Peyronie’s disease: a real life clinical report. Actas Urol Esp (Engl Ed). 2019;43:182–9.PubMedCrossRef
15.
16.
Paulis G, Cavallini G, De Giorgio G, et al. Long-term multimodal therapy (verapamil associated with propolis, blueberry, vitamin E and local diclofenac) on patients with Peyronie’s disease (chronic inflammation of the tunica albuginea). Results of a controlled study. Inflamm Allergy Drug Targets. 2013;12(6):403–9.PubMedCrossRef
17.
Brant WO, Dean RC, Lue TF. Treatment of Peyronie’s disease with oral pentoxifylline. Nat Clin Pract Urol. 2006;3(2):111–5.PubMedCrossRef
18.
Smith JF, Shindel AW, Huang YC, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie’s disease. Asian J Androl. 2011;13(2):322–5.PubMedCrossRef
19.
Payton S. Therapeutic benefit of pentoxifylline for Peyronie’s disease. Nat Rev Urol. 2010;7(5):237.PubMedCrossRef
20.
Alizadeh M, Karimi F, Fallah MR. Evaluation of verapamil efficacy in Peyronie’s disease comparing with pentoxifylline. Global J Health Sci. 2014;6(7):23–30.CrossRef
21.
Ciociola F, Colpi GM. Peyronie’s disease: a “triple oxygenant therapy.” Arch Ital Urol Androl. 2013;85(1):36–40.PubMedCrossRef
22.
Favilla V, Russo GI, Privitera S, et al. Combination of intralesional verapamil and oral antioxidants for Peyronie’s disease: a prospective, randomised controlled study. Andrologia. 2014;46(8):936–42.PubMedCrossRef
23.
24.
Kwon KD, Choi MJ, Park JM, et al. Silencing histone deacetylase 2 using small hairpin RNA induces regression of fibrotic plaque in a rat model of Peyronie’s disease. BJU Int. 2014;114(6):926–36.PubMedCrossRef
25.
Tal R, Hall MS, Alex B, Choi J, Mulhall JP. Peyronie’s disease in teenagers. J Sex Med. 2012;9(1):302–8.PubMedCrossRef
26.
Búfalo MC, Ferreira I, Costa G, et al. Propolis and its constituent caffeic acid suppress LPS-stimulated pro-inflammatory response by blocking NF-κB and MAPK activation in macrophages. J Ethnopharmacol. 2013;149(1):84–92.PubMedCrossRef
27.
Ebadi M, Sharma SK, Wanpen S, Amornpan A. Coenzyme Q10 inhibits mitochondrial complex-1 down-regulation and nuclear factor-kappa B activation. J Cell Mol Med. 2004;8:213–22.PubMedPubMedCentralCrossRef
28.
Karlsen A, Paur I, Bøhn SK, et al. Bilberry juice modulates plasma concentration of NF-kappaB related inflammatory markers in subjects at increased risk of CVD. Eur J Nutr. 2010;49(6):345–55.PubMedCrossRef
29.
Zhang DM, Guo ZX, Zhao YL, et al. l-Carnitine regulated Nrf2/Keap1 activation in vitro and in vivo and protected oxidized fish oil-induced inflammation response by inhibiting the NF-κB signaling pathway in Rhynchocypris lagowski Dybowski. Fish Shellfish Immunol. 2019;93:1100–10.PubMedCrossRef
30.
31.
32.
Tian MY, Fan JH, Zhuang ZW, et al. Effects of silymarin on p65 NF-κB, p38 MAPK and CYP450 in LPS-induced hoof dermal inflammatory cells of dairy cows. BMC Vet Res. 2019;15(1):127.PubMedPubMedCentralCrossRef
33.
Wang Y, Wang R, Wang Y, et al. Ginkgo biloba extract mitigates liver fibrosis and apoptosis by regulating p38 MAPK, NF-κB/IκBα, and Bcl-2/Bax signaling. Drug Des Dev Ther. 2015;9:6303–17.
34.
Wang WG, Xiu RJ, Xu ZW, et al. Protective effects of Vitamin C against spinal cord injury-induced renal damage through suppression of NF-κB and proinflammatory cytokines. Neurol Sci. 2015;36(4):521–6.PubMedCrossRef
35.
Godbout JP, Berg BM, Krzyszton C, Johnson RW. Alpha-tocopherol attenuates NFkappaB activation and pro-inflammatory cytokine production in brain and improves recovery from lipopolysaccharide-induced sickness behavior. J Neuroimmunol. 2005;169(1–2):97–105.PubMedCrossRef
36.
Costantini TW, Deree J, Peterson CY, et al. Pentoxifylline modulates p47phox activation and downregulates neutrophil oxidative burst through PKA-dependent and -independent mechanisms. Immunopharmacol Immunotoxicol. 2010;32(1):82–91.PubMedCrossRef
37.
Sunil VR, Vayas KN, Cervelli JA, et al. Pentoxifylline attenuates nitrogen mustard-induced acute lung injury, oxidative stress and inflammation. Exp Mol Pathol. 2014;97(1):89–98.PubMedPubMedCentralCrossRef
38.
Freitas JP, Filipe PM. Pentoxifylline. A hydroxyl radical scavenger. Biol Trace Elem Res. 1995;47(1–3):307–11.PubMedCrossRef
39.
Ji Q, Zhang L, Jia H, Xu J. Pentoxifylline inhibits endotoxin-induced NF-kappa B activation and associated production of proinflammatory cytokines. Ann Clin Lab Sci. 2004;34(4):427–36.PubMed
40.
Jin F, Li X, Lee HJ, Lee CJ. diclofenac inhibits phorbol ester-induced gene expression and production of MUC5AC mucin via affecting degradation of IkBα and translocation of NF-kB p65 in NCI-H292 cells. Biomol Ther (Seoul). 2020;28(5):431–6.PubMedPubMedCentralCrossRef
41.
Radermacher J, Jentsch D, Scholl MA, et al. Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease. Br J Clin Pharmacol. 1991;31(5):537–41.PubMedPubMedCentralCrossRef
42.
Hatzimouratidis K, Eardley I, Giuliano F, et al. EAU guidelines on penile curvature. Eur Urol. 2012;62(3):543–52.PubMedCrossRef
43.
McCauley JF, Dean RC. Diagnostic utility of penile ultrasound in Peyronie’s disease. World J Urol. 2020;38(2):263–8.PubMedCrossRef
44.
Parmar M, Masterson JM, Masterson TA 3rd. The role of imaging in the diagnosis and management of Peyronie’s disease. Curr Opin Urol. 2020;30(3):283–9.PubMedCrossRef
Metadata
Title
Patients with Peyronie’s disease achieve complete plaque regression after multimodal treatment with antioxidants: a case series
Authors
Gianni Paulis
Giovanni De Giorgio
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2022
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-022-03614-1

Other articles of this Issue 1/2022

Journal of Medical Case Reports 1/2022 Go to the issue

Case report

Sequential occurrence of recurrent Sweet syndrome and erythema nodosum without an underlying secondary cause: a case report

Case report

A presumptive association between obsessive compulsions and asymmetric temporal lobe atrophy: a case report

Case report

Ulceroglandular form of tularemia after squirrel bite: a case report

Case report

Ablation of typical atrial flutter as therapeutic component in carcinoid heart disease: a case report

Case report

Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report

Case report

5p deletion with congenital diaphragmatic hernia: a case report